Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia

References

• Robak T, Dmoszynska A, Solal-Celigny P, . Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1756–1765.
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Wen S, . Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070–4078.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164–1174.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009; 115: 2824–2836.
   PubMed Web of Science ®Google Scholar
• Zenz T, Eichhorst B, Busch R, . TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 4473–4479.
   PubMed Web of Science ®Google Scholar
• Zenz T, Habe S, Denzel T, . Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009; 114: 2589–2597.
   PubMed Web of Science ®Google Scholar
• Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001; 3: 137–143.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Hallek M. Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol 2009; 144: 818–831.
   PubMed Web of Science ®Google Scholar
• Osterborg A, Foa R, Bezares RF, . Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009; 23: 1980–1988.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V, . Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561.
   PubMed Web of Science ®Google Scholar
• Rai KR, Freter CE, Mercier RJ, . Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891–3897.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T, Winkler D, . Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009; 27: 3994–4001.
   PubMed Web of Science ®Google Scholar
• Lozanski G, Heerema NA, Flinn IW, . Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103: 3278–3281.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347: 452–453.
   PubMed Web of Science ®Google Scholar
• Nosari A, Montillo M, Morra E. Infectious toxicity using alemtuzumab. Haematologica 2004; 89: 1415–1419.
   PubMed Web of Science ®Google Scholar
• Nosari A, Tedeschi A, Ricci F, . Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab. Haematologica 2008; 93: e30–e31.
   PubMedGoogle Scholar
• Horner MJ RL, Krapcho M, Neyman N, editor. SEER Cancer Statistics Review, 1975–2006. National Cancer Institute, Bethesda (MD), available on line at http://seer.cancer.gov/csr/1975_2006/; 2009.
   Google Scholar
• Cortelezzi A, Pasquini MC, Gardellini A, . Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 2009; 23: 2027–2033.
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Pasquini MC, Sarina B, . A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia. Haematologica 2005; 90: 410–412.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Grever M, . National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.
   PubMed Web of Science ®Google Scholar
• Laurenti L, Piccioni P, Tarnani M, . Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience. Haematologica 2005; 90: 1143–1145.
   PubMed Web of Science ®Google Scholar
• Bezares RF, Stemelin G, Diaz A, . Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis. Leuk Lymphoma 2011 ; 52: 1936–1941.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki AB, Robak T, . Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 5616–5623.
   PubMed Web of Science ®Google Scholar
• Hale G, Rebello P, Brettman LR, . Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004; 104: 948–955.
   PubMed Web of Science ®Google Scholar
• Morris EC, Rebello P, Thomson KJ, . Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003; 102: 404–406.
   PubMed Web of Science ®Google Scholar
• Mould DR, Baumann A, Kuhlmann J, . Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 2007; 64: 278–291.
   PubMed Web of Science ®Google Scholar
• Hallek M, Pflug N. State of the art treatment of chronic lymphocytic leukaemia. Blood Rev 2011; 25: 1–9.
   PubMed Web of Science ®Google Scholar
• Elter T, Borchmann P, Schulz H, . Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005; 23: 7024–7031.
   PubMed Web of Science ®Google Scholar
• Kennedy B, Rawstron A, Carter C, . Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002; 99: 2245–2247.
   PubMed Web of Science ®Google Scholar